ReviewCurrent oncology (Toronto, Ont.)2025
Predicting the Risk for Pathological Fracture in Bone Metastases.
Review in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence and Machine Learning in Bone Metastasis Management: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 50-70% of patients with advanced cancer will experience bone metastases. The link between metastatic lesions and pathological bones is especially troubling since more metastases mean a higher chance of painful fractures, which can reduce mobility and often require surgery. Therefore, fracture risk predictions are essential for managing patients with bone metastases. However, the current methods for evaluating the risk of fractures are subjective, with low predictive value. This paper highlights how there being no effective comprehensive models for grouping patients by fracture risk due to skeletal metastases makes it harder to create personalized treatment plans; presents the methods currently used for objective evaluations of the pathological fracture risk in bone metastases; and discusses their pros and cons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.